NVG-222
Not Specified (Oncology/Haematological)
Phase 1Active
Key Facts
About NovalGen
NovalGen is an innovative UK-based biotech advancing a pipeline of multi-specific biologics powered by its novel AutoRegulation platform, designed to enhance safety and efficacy. The company is in the clinical stage, having initiated its first Phase 1 trial for a T-cell engager in 2026 and planning the world's first trial for a self-regulating immunotherapy. With strong academic roots from UCL and strategic partnerships, NovalGen is targeting significant unmet needs across immunology and oncology.
View full company profile